Drug discovery > Pre-Clinical Development Products & Reviews

BioPerformance Certified, meets EP, USP testing specifications, suitable for cell culture, ≥99.9% (titration)

Powder, pH 7.4, with 0.05% Tween® 20

lyophilized powder, 20 kDa

lyophilized powder, ≥900 units/mg protein

1,6-α-D-Glucan 6-glucanohydrolase

organic base and chaeotropic agent, ≥99% (titration)

BioPerformance Certified, ≥99.5% (titration), suitable for cell culture

Type III-A, ≥85% RNase A basis (SDS-PAGE), 85-140 Kunitz units/mg protein

USP Testing Specific

suitable for cell culture, ≥99.5%

≥99.0% (titration)

≥99.5% (titration)

Lyophilized, ~9 U/mg

suitable for cell culture, ≥99.5%

2-Amino-2-(hydroxymethyl)-1,3-propanediol

Functions as a coenzyme of a large number of oxidoreductases

CN Bio supports non-alcoholic steatohepatitis (NASH) therapeutic development via fast-track NASH Contract Research Services. NASH Services enable you to gain instant access to CN Bio’s expertise and one of the most advanced human in vitro models available. Submit lead candidates for screening and receive human translatable data for insightful preclinical candidate prioritization, clinical trial design and optimization.

CN Bio supports R&D efforts via fast-track Drug Metabolism and Safety Toxicity Testing Services that deliver human translatable insights from lead candidates in a few weeks and at lower cost than animal studies. By accessing the Company’s expertise and advanced in vitro liver-on-chip models, these Services enable researchers to step beyond standard in-house laboratory workflows for better informed pre-clinical decisions.

Fast-track your route to successful NASH therapeutic development with CN Bio's 3D NASH model.

High plex proteomics instrument for spatial biology

Fast track precise spatial multiplexing

Ultravap™ Levante Nitrogen Blow-Down Sample Concentrator

96-Channel Positive Displacement Sample Transfer

We offer extensive Toxicity & Safety Evaluation Services to identify potential risks in drug candidates early. Our comprehensive capabilities cover General, Local, Developmental, and Organ-Specific Toxicity (including liver, cardio, and neuro) across numerous animal species, administered via various routes, to characterize drug safety.